Spero Therapeutics, Inc. (NASDAQ:SPRO) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, SPRO to report 3Q20 loss of $ 0.87 per share.
For the full year, analysts anticipate top line of $ 10.76 million, while looking forward to loss of $ 3.55 per share bottom line.
Previous Quarter Performance
Spero Therapeutics, Inc. disclosed loss for the second quarter of $ 0.85 per share, from the revenue of $ 1.73 million. The quarterly revenues shrunk 19.91 percent compared with the same quarter last year. According to street consensus, SPRO was expected to report 2Q20 loss of $ 1.12 per share from revenue of $ 3.40 million. The bottom line results beat street analysts by $ 0.27 or 24.11 percent, at the same time, top line results fell short of analysts by $ 1.67 million or 49.12 percent.
Stock Performance
Shares of Spero Therapeutics, Inc. traded low $ -0.28 or -1.98 percent on Wednesday, reaching $ 13.87 with volume of 259.10 thousand shares. Spero Therapeutics, Inc. has traded high as $ 14.85 and has cracked $ 13.74 on the downward trend
The closing price of $ 13.87, representing a 169.52 % increase from the 52 week low of $ 5.25 and a 4.71 % decrease over the 52 week high of $ 14.85.
The company has a market capital of $ 360.21 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 29th September 2020, initiated by Evercore ISI at Outperform rating, with $ 70.00 target price.
Conference Call
Spero Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website sperotherapeutics.com
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc.
